Century Therapeutics (IPSC) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 129.0% versus a gain of 23.1%. Over five years, IPSC leads with a -93.4% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($255.7 million vs $224.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | SABS |
|---|---|---|
| Share price | $1.24 | $2.81 |
| Market cap | $224.53M | $255.67M |
| 1-day change | -3.12% | -2.43% |
| YTD return | +28.64% | -22.99% |
| 1-year return | +128.98% | +23.08% |
| 5-year return | -93.37% | -97.15% |
| EPS (TTM) | $-0.93 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $5.15 |
| 52-week low | $0.435 | $2.10 |
| Distance from 52-week high | -59.21% | -45.44% |
| Analyst consensus | buy | none |
| Avg. price target upside | +283.06% | +314.23% |
| Average volume | 649.61K | 489.83K |
| Shares outstanding | 181.08M | 90.99M |
| Employees | 78 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed SABS by 105.9 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
IPSC vs SABS FAQ
Which is bigger, Century Therapeutics or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $255.67M compared with $224.53M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or SABS?
IPSC returned +128.98% over the past 12 months, compared with +23.08% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.